에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

Reiteration

Analyst Ratings

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

General

Booz Allen Partners With Shield AI To Deliver AI-Enabled Software-Defined Autonomous Solutions For US Government

Earnings

ETON

Eton Pharmaceuticals Q4 2024 GAAP EPS $(0.02) Vs. $(0.09) YoY, Sales $11.65M Beat $10.53M Estimate

Guidance

CTRN

Citi Trends Sees FY25 Comparable Store Sales Growth Of Low To Mid-Single Digits

Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $0.18 by 1050 percent. This is a 422.64 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $211.17 million which missed the analyst consensus estimate of $211.54 million by 0.17 percent. This is a 1.86 percent decrease over sales of $215.18 million the same period last year.

Earnings Misses

Citi Trends Q4 Adj $(1.71) Misses $0.18 Estimate, Sales $211.17M Miss $211.54M Estimate

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) with a Buy and maintains $11 price target.

Price Target

SANA

HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $11 Price Target

NIO Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)&nbsp;shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">higher in the premarket </a>session on Tuesday.
NIO and Contemporary Amperex Technology Co., Ltd. (CATL) have <a target="_blank" href="https://www.nio.com/news/20250318001" rel="noreferrer noopener">joined </a>forces to enhance the development of the new energy vehicle sector.
On Monday, the companies announced a strategic partnership to establish a comprehensive battery swapping network for passenger vehicles, optimize industry standards, and provide efficient recharging solutions.
William Li, founder and CEO of NIO, and Dr. Robin Zeng, chairman and CEO of CATL, were both present at the signing ceremony, marking the beginning of this major strategic venture.
NIO has established a vast network of charging and battery swapping stations across China, surpassing 3,000 Power Swap Stations.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44359600/hyperfine-nvidia-partner-to-make-brain-mris-more-affordable" rel="noreferrer noopener">Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable</a>
The company aims to expand this network considerably by 2025, reaching additional cities and county-level areas.
In March 2024, NIO and CATL inked a framework agreement to promote innovation in the R&amp;D of long-life batteries jointly.
&#8220;The strategic cooperation between NIO and CATL marks a pivotal moment, propelling battery swapping into a brand-new phase,&#8221; said Li.
CATL&#8217;s investment of up to RMB 2.5 billion (~$346 million) in NIO Power will strengthen this strategic partnership. CATL will assist NIO in enhancing its battery-swapping network. Additionally, they will collaborate to establish national standards for battery-swapping technology in China, which will improve compatibility among various brands.
&#8220;Leveraging our Choco-Swap and the parallel operations of both CATL&#8217;s and NIO&#8217;s networks, we are able to build a smart power network that caters to a wide range of needs across multiple levels and dimensions. This will enable every battery to deliver greater value throughout its lifecycle, and allow us to provide global users with safer, more efficient, and more sustainable electric mobility solutions,&#8221; said Zeng.
NIO will report its fourth quarter&nbsp;results on Friday, March 21, 2025, before the open of the U.S. markets.
Price Action: NIO shares traded higher by 5.77% at $5.32 in premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44358047/pepsico-bets-big-on-prebiotic-sodas-with-1-95-billion-poppi-acquisition-details" target="_blank" rel="noreferrer noopener">PepsiCo Bets Big On Prebiotic Sodas With $1.95 Billion Poppi Acquisition: Details</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Contracts

What's Going On With NIO Stock Today?

B of A Securities analyst Julien Dumoulin-Smith maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Buy and raises the price target from $108 to $114.

B of A Securities Maintains Buy on American Electric Power, Raises Price Target to $114

B of A Securities analyst Allen Lutz maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and raises the price target from $21 to $22.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) with a Buy and maintains $100 price target.

BLTE

HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $100 Price Target

BBAI

BigBear.ai Estimates Restatement To Change 2023 Income Before Taxes To $(71.3)M From Prior $(60.3)M, To Change 2024 Income Before Taxes To $(296.1)M From Prior $(257.1)M

VIAV

VIAVI Launches 800G Module Expanding Portfolio Of High-Speed Test Solutions

Carter's Launches Spring Break Collection Curated By Social Media Star Baby Kate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) with a Buy and maintains $10 price target.

GOSS

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

BigBear.ai Identifies Need To Restate Certain Prior Financial Statements - Filing

Health Care

CMPS

Compass Pathways Publishes Results From COMP360 Psilocybin Study Indicating Longer-Term antidepressant Effects With 25mg Dose

This LOI builds on the existing Development Service Agreement between Solterra and SB Impact 4, which granted exclusivity to SB Impact 4 and N2OFF for evaluating and potentially acquiring these projects within a 60-day period.

NITO

N2OFF Signs Non-binding Letter Of Intent With SB Impact 4 And Solterra Brand Services Italy

Needham analyst Mike Matson maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Buy and lowers the price target from $108 to $104.

Needham Maintains Buy on Haemonetics, Lowers Price Target to $104

OUST

Ouster Launches Cloud Portal For Ouster Gemini

Morgan Stanley analyst Adam Jonas upgrades Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) from Underweight to Equal-Weight and announces $3 price target.

Upgrades

LCID

Morgan Stanley Upgrades Lucid Group to Equal-Weight, Announces $3 Price Target

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Truist Securities

Leerink Partners

HC Wainwright & Co.

BMO Capital

Morgan Stanley

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요?
1. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 <a href="https://www.benzinga.com//node/44236516" target="_blank" rel="noreferrer noopener">비공개 금액에 인수하기로 합의</a>했다. 애널리스트들은 이 회사의 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 하향 조정</a>했다.
2. 트레이드 데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>)의 주가가 16.90% 급락했다. 이는 아마도 관세와 무역 정책으로 인한 경제적 우려 때문이다.
3. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주가가 15.79% 하락했다. 이는 <a href="https://www.benzinga.com//node/44287858" target="_blank" rel="noreferrer noopener">비트코인이 관세 불확실성으로 인해 하락</a>했기 때문이다.
4. 세일포인트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>)의 주가가 15.19% 하락했다.
5. 젠맙(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>)의 주가가 15.04% 하락했다. 이는 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 HexaBody-CD38에 대한 전 세계 개발, 제조 및 상용화 라이선스를 받을 옵션을 행사하지 않기로 결정한 후 발생한 일이다. 젠맙은 <a href="https://www.benzinga.com//node/44221409" target="_blank" rel="noreferrer noopener">추가 임상 개발을 진행하지 않기로</a> 했다.
6. 인터랙티브 브로커스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>)의 주가가 12.52% 하락했다. 이는 아마도 관세 불확실성으로 인한 전반적인 시장 우려 때문일 것이다.
7. 델타 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>)의 주가가 12.26% 급락했다. 회사가 첫 분기 <a href="https://www.benzinga.com//node/44244750" target="_blank" rel="noreferrer noopener">매출과 이익 가이던스를 하향 조정</a>했기 때문이다.
8. 어도비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)의 주가가 12.16% 하락했다. 이는 회사가 2분기 및 2025 회계연도 조정 EPS 가이던스를 발표했으며, 그 중간값이 예상보다 낮았기 때문이다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/44302063" target="_blank" rel="noreferrer noopener">가격 전망을 수정</a>했다.
9. 익스피디아 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)의 주가가 12.05% 하락했다. 이는 여행 관련 주식들이 <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">전반적인 매도세</a>로 인해 하락한 후 발생한 일이다. <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">델타 항공이</a><a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener"> 가이던스 하향 조정</a>을 발표했다.
10. 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 주가가 11.66% 하락했다. 회사는 <a href="https://www.benzinga.com//node/44252567" target="_blank" rel="noreferrer noopener">2월 운영 데이터를 발표</a>했다.
11. 유나이티드 항공 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)의 주가가 11.11% 하락했다. 이는 BofA 증권과 바클레이즈가 주식에 대한 <a href="https://www.benzinga.com/quote/ual/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 가격 전망을 하향 조정</a>했기 때문다.
12. 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 주가가 10.70% 하락했다. 이는 지속적인 관세 불확실성으로 인한 전반적인 시장 약세 때문이다.
사진 제공: Useacoin, Shutterstock
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%95%B1%EB%9F%AC%EB%B9%88-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EC%9D%B8%ED%85%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EA%B8%89%EB%93%B1%ED%95%9C/" target="_blank" rel="noopener">앱러빈, 슈퍼 마이크로 컴퓨터, 인텔 등 지난주 급등한 대형주 10종목 (3월 10일-3월 14일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Genmab

뉴스

에 대한 최신 뉴스 Genmab (NASDAQ:GMAB) 주식

일요일, 3월 16, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌